Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, two-way crossover study

Clinical Therapeutics

Volumn 32, Issue 1, 2010, Pages 171-178

  Zhang, Qian ^a   Tao, Yifu ^a   Zhu, Yubing ^a   Zhu, Dingchun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

bioequivalence; HPLC; mycophenolate mofetil; mycophenolic acid; pharmacokinetics

Indexed keywords

DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; BIOAVAILABILITY; BLOOD; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MICROCAPSULE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; TABLET; TANDEM MASS SPECTROMETRY; TIME;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CAPSULES; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOPHENOLIC ACID; REFERENCE VALUES; TABLETS; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; TIME FACTORS; YOUNG ADULT;

MLCS; MLOWN;

EID: 77952308219     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.013     Document Type: Article

References (20)

1. Krejci, M, Doubek, M, Buchler, T, et al. Mycophenolate mofetil for the treatment of acute and chronic steroidrefractory graft-versus-host disease. Ann Hematol 84 (2005), 681–685.
2. Protic, A, Zivanovic, Lj, Zecevic, M, Jocic, B, Development of liquid chromatographic method for simultaneous determination of mycophenolate mofetil and its degradation product mycophenolic acid in dosage form. J Chromatogr 47 (2009), 149–155.
3. Tan, CH, Loh, PT, Yang, WS, Chan, CM, Mycophenolate mofetil in the treatment of IgA nephropathy: A systematic review. Singapore Med J. 49 (2008), 780–785.
4. Bullingham, RE, Nicholls, AJ, Kamm, BR, Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34 (1998), 429–455.
5. Bullingham, RE, Nicholls, A, Hale, M, Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant Proc. 28 (1996), 925–929.
6. de Winter, BC, van Gelder, T, Glander, P, et al. Population pharmacokinetics of mycophenolic acid: A comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet 47 (2008), 827–838.
7. Armstrong, VW, Shipkova, M, Schütz, E, et al., German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Monitoring of mycophenolic acid in pediatric renal transplant recipients. Transplant Proc. 33 (2001), 1040–1043.
8. Weber, LT, Shipkova, M, Armstrong, VW, et al. The pharmacokinetic pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13 (2002), 759–768.
9. Jiao, Z, Zhong, JY, Zhang, M, et al. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: Pharmacokinetics and application of limited sampling strategies. Eur J Clin Pharmacol 63 (2007), 27–37.
10. Yau, WP, Vathsala, A, Lou, HX, Chan, E, Is a standard fixed dose of mycophenolate mofetil ideal for all patients?. Nephrol Dial Transplant 22 (2007), 3638–3645.
11. Zicheng, Y, Peijun, Z, Da, X, et al. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. Br J Clin Pharmacol 62 (2006), 446–452.
12. Chen, H, Gu, Z, Chen, B, et al. Models for the prediction of mycophenolic acid area under the curve using limitedsampling strategy and an enzyme multiplied immunoassay technique in Chinese patients undergoing liver transplantation. Clin Ther. 30 (2008), 2387–2401.
13. Roda, A, Sabatini, L, Barbieri, A, et al. Development and validation of a sensitive HPLC-ESI-MS/MS method for the direct determination of glucosamine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 844 (2006), 119–126.
14. Bullingham, R, Monroe, S, Nicholls, A, Hale, M, Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36 (1996), 315–324.
15. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for Industry: Human drugs in vivo bioequivalence compliance program 7348.001. http://www.fda.gov/ora/complianceref/bimo/7348_001/default.htm Accessed March 3, 2009.
16. US Dept of Health and Human Services, Food and Drug Administration. Approval of Supplemental New Drug Application 21-066/S-011. http://www.fda.gov/cder/foi/Appletter/2006/O21066s01lltr.pdf Accessed September 6, 2007.
17. US Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry. Bioanalytical method validation. http://www.fda.gov/cder/guidance/4252fnl.htm Accessed August 16, 2006.
18. Schuirmann, DJ, A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15 (1987), 657–680.
19. US Dept of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations, 2002 http://www.fda.gov/cder/guidance/4964dft.htm Accessed January 28, 2008.
20. US Food and Drug Administration. In vivo bioequivalence guidances. Pharmacopeia Forum 19 (1993), 6501–6508.